Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CCR8 | P51685 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5428336 | 0.94 | CCR8 (0.44) | MEN1KMT2ACCR8KCNH2KDM4E | |
| SCHEMBL5429063 | 0.88 | NPC1 (0.40) | NPC1RAB9AMEN1KMT2ACCR8 | |
| SCHEMBL5434929 | 0.86 | KCNH2 (0.44) | MEN1KMT2ACCR8KCNH2USP2 | |
| SCHEMBL5433649 | 0.86 | CCR8 (0.46) | MEN1KMT2ACCR8KCNH2KDM4E | |
| SCHEMBL5431110 | 0.85 | CCR8 (0.46) | CCR8KCNH2KDM4EALOX15USP2 | |
| SCHEMBL5436923 | 0.85 | CCR8 (0.46) | CCR8KCNH2KDM4EALOX15USP2 | |
| SCHEMBL5428448 | 0.85 | CCR8 (0.46) | CCR8KCNH2KDM4EALOX15USP2 | |
| SCHEMBL5428130 | 0.85 | CCR8 (0.46) | CCR8KCNH2KDM4EALOX15USP2 | |
| SCHEMBL5431367 | 0.85 | KCNH2 (0.42) | CCR8KCNH2KDM4E | |
| SCHEMBL5436273 | 0.85 | CCR8 (0.43) | MEN1KMT2ACCR8KCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249648-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| EP-1678178-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040167-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249648-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases | CCR8, CCR1, CCR10 | NPC1 372/4885RAB9A 1738/4885MEN1 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.